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 2
Abstract 24 
Streptococcus pneumoniae is one of the key pathogens responsible for otitis media (OM), 25 
the most common infection in children and the largest cause of childhood antibiotic 26 
prescription. Novel therapeutic strategies that reduce the overall antibiotic consumption 27 
due to OM are required because although widespread pneumococcal conjugate 28 
immunization has controlled invasive pneumococcal disease, overall OM incidence has not 29 
decreased. Biofilm formation represents an important phenotype contributing to the 30 
antibiotic tolerance and persistence of S. pneumoniae in chronic or recurrent OM. We 31 
investigated the treatment of pneumococcal biofilms with nitric oxide (NO), an endogenous 32 
signaling molecule and therapeutic agent that has been demonstrated to trigger biofilm 33 
dispersal in other bacterial species. We hypothesised that addition of low concentrations of 34 
NO to pneumococcal biofilms would improve antibiotic efficacy and higher concentrations 35 
exert direct antibacterial effects.  Unlike in many other bacterial species, low 36 
concentrations of NO, did not result in S. pneumoniae biofilm dispersal. Instead, treatment 37 
of both in vitro biofilms and ex vivo adenoid tissue samples (a reservoir for S. pneumoniae 38 
biofilms) with low concentrations of NO enhanced pneumococcal killing when combined 39 
with amoxicillin-clavulanic acid, an antibiotic commonly used to treat chronic OM.  40 
Quantitative proteomic analysis using iTRAQ (isobaric tag for relative and absolute 41 
quantitation) identified 13 proteins that were differentially expressed following low-42 
concentration NO treatment, 85% of which function in metabolism or translation.  43 
Treatment with low-concentration NO therefore appears to modulate pneumococcal 44 
metabolism and may represent a novel therapeutic approach to reduce antibiotic tolerance 45 
in pneumococcal biofilms. [245] 46 
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Introduction 47 
Streptococcus pneumoniae is a Gram-positive bacterium that asymptomatically 48 
colonizes the human nasopharynx. This opportunistic pathogen is responsible for invasive 49 
diseases such as pneumonia, bacteremia and meningitis, and localized mucosal infections 50 
such as otitis media and sinusitis.  Globally, these infections represent a significant burden 51 
of disease, particularly in the very young and the elderly.  The World Health Organization 52 
estimates that 1.6 million deaths occur annually due to pneumococcal infections, 53 
accounting for around 11% of the mortality in children under 5 (1). The majority of deaths 54 
occur in developing countries where invasive pneumococcal disease remains one of the 55 
most common fatal childhood illnesses.  56 
Pneumococcus is a leading pathogen in otitis media (OM), the most common 57 
infection in young children and a principal reason for repeated physician visits. Upon 58 
colonization with S. pneumoniae and the establishment of carriage in children, bacteria may 59 
access the middle ear space by retrograde ascent from the nasopharynx due to the 60 
presence of fluid and/or disruption of mucociliary clearance.  Recurrent or chronic otitis 61 
media causes much pain and morbidity at high economic cost to society (2). In spite of 62 
concerns about the selection of antibiotic resistant bacteria, OM continues to be the 63 
primary reason for antibiotic prescription in children (3–5). In addition, although 64 
pneumococcal conjugate vaccines (PCV) have reduced vaccine type invasive pneumococcal 65 
disease, PCVs have not led to a decrease in the incidence of otitis media due to 66 
pneumococci, most likely due to non-vaccine type replacement (1, 6, 7). Novel treatments 67 
for pneumococcal infection are therefore needed to address the problem of recurrent 68 
and/or chronic infections in children. 69 
 4
Infections occur following a breach of the mucosal epithelia subsequent to 70 
colonization and despite being a prerequisite for infection, little is known about how 71 
pneumococci colonize and persist in the nasopharynx.  However, a growing body of 72 
literature suggests that bacterial biofilm development plays a prominent role in 73 
colonization and disease.  In situ investigation of paediatric middle ear biopsies indicated 74 
that pneumococcal biofilms were present on the middle ear mucosal epithelium in children 75 
with chronic OM but not in children without chronic OM (8, 9). S. pneumoniae biofilms have 76 
also been identified in situ on adenoid mucosal epithelia from children undergoing 77 
adenoidectomy for the treatment of infective (chronic OM) or inflammatory (obstructive 78 
sleep apnoea - OSA) otolaryngological disease consistent with the adenoid serving as a 79 
reservoir of pathogens that may contribute to infection under circumstances that favor 80 
middle ear infection (10, 11). More recently, pneumococcal biofilms have been investigated 81 
with animal models and epithelial cell models (12–15).    82 
Biofilms are highly adaptive surface-associated microbial aggregates that allow 83 
bacteria to survive the diverse stressful conditions encountered in the host such as nutrient 84 
limitation and host immune responses (16–19). The increased tolerance of biofilm bacteria 85 
to conventional antibiotic therapeutic concentrations compared with their planktonic 86 
counterparts also poses a significant problem in clinical settings, as does their propensity 87 
to acquire further antimicrobial resistance via horizontal gene transfer, underscoring the 88 
need for novel therapeutic strategies to limit the pneumococcal biofilm phenotype during 89 
disease (20, 21). 90 
Nitric oxide (NO) is an important signaling molecule that is ubiquitous in both 91 
eukaryotes and prokaryotes, bridging the boundaries between host and pathogen.  In the 92 
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human host, NO plays an important role in the innate immune response and is produced by 93 
inducible nitric oxide synthases (iNOSs) in epithelial and phagocytic cells with its 94 
production resulting in damage to bacterial cell membranes and DNA (22). Bacteria have 95 
also been shown to possess NOSs that oxidise L-arginine to produce the low concentrations 96 
of NO observed in several species (23, 24). Multiple regulatory systems have been 97 
identified that mediate the diverse responses of bacteria to NO, including conferring 98 
protection from oxidative stress and playing a role in toxin biosynthesis (23, 25). In 99 
biofilms, however, low concentrations of exogenous NO have been shown to trigger a 100 
dispersal response in several bacterial species including Pseudomonas aeruginosa, 101 
Escherichia coli and Staphylococcus epidermidis, a response associated with increased 102 
antibacterial efficacy when used as an adjuvant in conjunction with antibiotics (26–28).  103 
Furthermore, NO-releasing nanoparticles and gaseous NO have been shown to exert potent 104 
antimicrobial effects against P. aeruginosa, Streptococcus pyogenes and Enterococcus 105 
faecalis (29–31).   106 
Previous investigations into the role of NO in pneumococcal infection have given 107 
conflicting results. In a murine pneumonia model NO was found to be associated with 108 
increased bacterial loads and reduced survival during bacteremia in wild-type mice but not 109 
in NOS2-deficient mice.  In contrast during pneumonia following intranasal infection NO 110 
decreased pneumococcal viability in the lung in both mouse strains via a direct 111 
antibacterial effect (32).  112 
 Because several studies using biofilm models have shown that low concentrations of 113 
NO trigger release of bacteria from the biofilm in various bacterial species we hypothesized 114 
that adjunctive NO treatment would also improve the efficacy of antibiotic killing of 115 
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pneumococci in biofilms.  We tested this hypothesis using in vitro and ex vivo pneumococcal 116 
biofilms. Biochemical studies and a high-throughput quantitative proteomic approach were 117 
utilized to interrogate possible mechanisms of action.  118 
 119 
Methods 120 
Bacterial strains and growth conditions. Clinical isolates of Streptococcus pneumoniae 121 
serotypes 14 (ST124), 19F and 23F (33), and the laboratory strain D39 (serotype 2) were 122 
selected to evaluate the in vitro antibacterial efficacy of NO and antibiotic adjunctive 123 
treatment. Strains were subcultured from frozen stocks onto Columbia blood agar (CBA) 124 
plates (Oxoid, U.K.) as described (33).  Briefly, cultures were incubated at 37oC/5% CO2 and 125 
colonies re-suspended in fresh Brain Heart Infusion (BHI) broth (Oxoid, U.K.) for 126 
experiments. 127 
 128 
Planktonic experiments. Flat-bottomed 96-well culture plates (Fisher Scientific, U.K.) 129 
were inoculated with ~1.0 x 107 bacteria per well (mid-exponential planktonic cultures) 130 
grown in BHI. All treatments were prepared in BHI. Sodium nitroprusside dihydrate (SNP) 131 
was added to wells for final concentrations ranging from 1 μM to 10 mM; diethylamine 132 
NONOate (DEA/NO; sodium salt), sodium nitrate (NaNO3), sodium nitrite (NaNO2) and 133 
potassium cyanide (KCN; all Sigma-Aldrich, U.K.) were added at a final concentration of 1 134 
mM, and carboxy-PTIO potassium salt and L-methionine (both Sigma-Aldrich, U.K.) were 135 
added at final concentrations of 50 μM and 1 mM respectively. BHI was added in place of 136 
treatments for all untreated controls.  BHI alone was used to measure background changes 137 
in absorbance. Cultures were incubated at 37oC/5% CO2 and absorbance (OD595) 138 
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measured every 30 min over 2 hours using an EZ Read 400 spectrophotometer (Biochrom) 139 
(n=3).  140 
 141 
In vitro biofilm experiments. For biofilm formation mid-exponential planktonic cultures 142 
grown in BHI were used to inoculate individual wells of untreated polystyrene 6-well 143 
plates (1 x 108 cells per well) (Corning Incorporated, Costar, U.S.A.), and supplemented 144 
with fresh BHI diluted 1:5 in distilled H2O. Cultures were incubated at 37oC/5% CO2 with 145 
replacement of warm, fresh diluted 1:5 BHI daily for 2 to 7 days. 146 
Prior to treatment medium was removed and biofilms washed twice using diluted 147 
1:5 BHI. NO donor (SNP and DEA/NO) treatments were prepared fresh in diluted 1:5 BHI 148 
and added to wells at final concentrations ranging from 100 nM to 1 mM.  For adjuvant 149 
experiments amoxicillin + clavulanic acid (AMC) was added at a final concentration of 150 
300/60 μg/ml. Biofilms were incubated at 37oC/5% CO2 for 2 hours after which the NO 151 
donors or inhibitors were removed and the remaining biofilm rinsed twice with diluted 1:5 152 
BHI. Biofilms were resuspended in Hank’s balanced salt solution (HBSS) as described (20). 153 
Briefly, biofilms were scraped and vortexed, both resuspended biofilms and removed 154 
supernatants were diluted in HBSS, spot plated onto CBA plates and incubated at 37oC/5% 155 
CO2. To assess total biofilm biomass 100 μl of the resuspended biofilms were diluted 10-156 
fold in 1:5 BHI and turbidity measured by absorbance (OD595) using a Jenway 6300 157 
spectrophotometer. All assays were performed on 48 h biofilms using 2 technical replicates 158 
of 2 biological replicates (n=4).  159 
 160 
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Confocal Laser Scanning Microscopy (CLSM). Mid-exponential planktonic cultures of 161 
strain ST124 (n=3) were grown in BHI and used to inoculate 35 mm untreated glass 162 
bottom CELLview cell culture dishes (Greiner Bio One, U.K.) and supplemented with fresh 163 
1:5 BHI. Biofilms were grown under static conditions at 37oC/5% CO2 for 48 h replacing 164 
medium daily with fresh 1:5 BHI. Biofilms were treated with 1 mM SNP in 1:5 BHI or 1:5 165 
BHI (untreated control) at 37oC/5% CO2 for 2 hours. Treatments were removed and the 166 
remaining biofilm rinsed twice with HBSS. Biofilms were stained with Live/Dead BacLight 167 
Bacterial Viability Kit (Life Technologies, U.S.A.) according to manufacturer instructions. 168 
Biofilms were examined immediately with an inverted Leica SP8 LSCM system using a 63x 169 
oil immersion lens and sequential scanning of 1 μm sections (Leica Microsystems, Milton 170 
Keynes, U.K.). To remove background eDNA staining, the Syto9 fluorescence intensity 171 
threshold was set to that of planktonic pneumococci. Images were analysed using Leica LCS 172 
Software.  173 
 174 
Scanning Electron Microscopy (SEM). Serotype 14 (ST124) biofilms were grown for 48 h 175 
in 6-well plates containing ethanol-sterilized 13 mm glass cover slips (V.W.R., U.K.). 176 
Biofilms were treated with 1 mM SNP in 1:5 BHI or 1:5 BHI (untreated control) at 37oC/5% 177 
CO2 for 2 hours then processed for SEM as described (33). Biofilms were imaged using an 178 
FEI Quanta 200 scanning electron microscope. 179 
 180 
Protein extraction and iTRAQ (isobaric tag for relative and absolute quantitation) 181 
labelling. Comparative analyses of protein expression between biofilms treated with 100 182 
μM SNP for 2 h at 37oC/5% CO2 and untreated biofilms were performed on 3 technical 183 
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replicates of 3 biological replicates. Protein extraction and iTRAQ labelling were performed 184 
as described (33). 185 
 186 
Mass spectrometry, peak list generation, and database searching. Mass spectrometry, 187 
peak list generation and database searching were performed as previously described (33). 188 
Inclusion criteria for quantitative analysis were set at ≥3 peptide matches, ≥50 protein 189 
score, ≥5% sequence coverage (p < 0.05). Comparative protein data with >1.3 and <0.77 190 
ratios were identified as having differential expression. For qualitative identification the 191 
inclusion criteria were 2 peptide matches, ≥50 protein score, and ≥5% sequence coverage. 192 
 193 
Ex vivo adenoid experiments. Adenoids were obtained from paediatric patients <12 years 194 
of age undergoing adenoidectomy for the treatment of suspected inflammatory or infective 195 
Ear, Nose and Throat (ENT) disease (n=11).  Adenoids were collected on ice in sterile HBSS 196 
+ 5% fetal bovine serum (FBS; Sigma-Aldrich, U.K.), washed twice with HBSS to remove any 197 
unattached bacteria, then dissected into four equal-sized sections with similar luminal 198 
surface coverage.  Tissue sections were normalized for weight and treated with 100 μM 199 
SNP alone, 300/60 μg/ml AMC alone or 100 μM SNP + 300/60 μg/ml AMC in HBSS/10% 200 
FBS for 2 h at 37oC/5% CO2. Untreated control tissue was treated with HBSS/10% FBS 201 
alone.  Tissue sections were washed twice with 10 ml HBSS, macerated in 1 ml HBSS 202 
through a 100 μm nylon cell strainer (Fisher Scientific, U.K.) and bacterial suspensions 203 
serially diluted and spot plated onto CBA plates.  204 
 205 
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Statistical analyses. Statistical analysis of in vitro planktonic and biofilm data was 206 
performed using one-way ANOVA and Tukey’s multiple comparisons tests. Analysis of ex 207 
vivo adenoid data was performed using a Wilcoxon Signed Ranks test. Comparative data 208 
reported as p<0.05 were considered statistically different.  209 
 210 
Results 211 
Treatment with the NO donor SNP decreased viability of planktonic cells and the cell 212 
population remaining within in vitro biofilms. Since low-concentrations of NO have 213 
been shown to result in the release or dispersal of other bacterial species from biofilms, we 214 
first tested the hypothesis that low-concentrations of NO would have a similar effect on 215 
pneumococcal biofilms.  Established 48 hour biofilms were treated for 2 hours with a range 216 
of NO concentrations generated from different concentrations of the NO-donor SNP (100 217 
nM - 1 mM; Fig. 1).  Measurement of biofilm biomass using turbidity, and viability using 218 
colony forming unit (CFU) enumeration, respectively, indicated that treatment with low 219 
concentrations of NO (100 nM to 100 μM SNP) did not have a similar effect on 48h 220 
pneumococcal biofilms. Treatment with 1 mM SNP however, resulted in a significant 221 
reduction in the biomass and a 3-log reduction in the number of viable cells remaining 222 
within the biofilm (p≤0.001). These results suggested that at 1mM SNP treatment may 223 
either be triggering the release of S. pneumoniae from the biofilm or had a direct 224 
bactericidal effect. To distinguish between these possibilities the number of viable cells 225 
present in the biofilm supernatant was measured following treatment with 1 mM SNP. 226 
Results indicated that there was a significant reduction in planktonic pneumococcal cells 227 
suspended in the supernatant as well as in the biofilm following NO treatment (Fig. 2, 228 
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p≤0.05).  Since NO treatment of biofilms formed by other bacterial species typically results 229 
in increased numbers of bacterial CFUs in the supernatant (24) these data indicated that 230 
treatment with higher concentrations of SNP had a direct antibacterial killing effect. 231 
Furthermore, both SEM and CLSM imaging of biofilms treated with 1 mM SNP 232 
demonstrated no significant change in biofilm ultrastructure following treatment 233 
confirming the lack of dispersal (Fig. 3a-b, 3e-f). CLSM imaging did, however, demonstrate 234 
a reduction in the number of viable cells remaining within the biofilm following treatment, 235 
commensurate with the observed 3-log reduction in CFUs (Fig. 3c-d). To confirm that 236 
higher NO concentrations were toxic for pneumococcus, mid-exponential planktonic 237 
cultures were treated with the same range of concentrations of SNP.  Cultures treated with 238 
SNP concentrations between 1 μM to 10 mM for 2 hours showed a significant reduction in 239 
growth with 500 μM to 5 mM SNP (p≤0.05), and complete cessation of growth with 240 
concentrations greater than 5 mM (Fig. 4).   241 
 242 
The response of S. pneumoniae to treatment with SNP was mediated by NO. Having 243 
determined that both planktonic and biofilm pneumococci responded to SNP treatment, we 244 
next wished to confirm that the response was indeed mediated by NO and not due to other 245 
NO metabolites, intact SNP or SNP breakdown products other than NO.  Treatment with 1 246 
mM KCN, a control for the possible effect of cyanide anion liberation from the SNP 247 
molecule, caused no reduction in pneumococcal growth confirming that the reduction in 248 
viability compared with untreated bacteria was not due to cyanide toxicity (p=0.528; Fig. 249 
5a).  Moreover, treatment with 1 mM DEA/NO, an alternative NO-donor molecule that is 250 
chemically and mechanistically distinct from SNP, resulted in a significant decrease in 251 
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growth, similar in extent to treatment with 1 mM SNP (p=0.013, Fig, 5a), whilst treatment 252 
with the NO-scavenger cPTIO abrogated the response to SNP (p=0.008, Fig. 5b). These 253 
results indicated that the response to SNP treatment was NO-mediated.  254 
In contrast, treatment with 1 mM nitrate (p=0.321) or nitrite (p=0.078) failed to 255 
significantly reduce pneumococcal growth, indicating that the oxidative breakdown 256 
products of NO were not responsible for the observed reduction in viability (Fig. 5a).  Since 257 
peroxynitrite (ONOO-) is an extremely toxic molecule that can be produced by reaction of 258 
NO with superoxide (O2-) to cause damage to DNA, proteins and lipids (24, 29), we further 259 
tested whether ONOO- toxicity might be involved in reducing pneumococcal viability 260 
during SNP treatment by using the ONOO- scavenger L-methionine. Indeed, the response to 261 
SNP was also reduced by the presence of L-methionine (p=0.005) suggesting that 262 
extracellular ONOO- formation secondary to reaction with O2- might be responsible for the 263 
bactericidal effects of higher concentrations of NO on pneumococcal cells (Fig. 5c).  264 
 265 
NO adjunctive treatment of in vitro pneumococcal biofilms enhanced antibiotic 266 
effectiveness. Others have shown that NO combined with antibiotic treatment resulted in 267 
an additional reduction in the viability of biofilms in several types of bacteria (28).  We 268 
therefore tested whether NO treatment of pneumococcal biofilms could further reduce 269 
bacterial viability when used as an adjunctive treatment in conjunction with a conventional 270 
antibiotic used to treat otitis media.  Serotype 2 strain D39 biofilms and biofilms from 3 271 
different clinical isolates representative of serotypes 14 (ST124), 19F and 23F  and based 272 
on their high isolation frequency in OM (20) and high rates of antibiotic recalcitrance were 273 
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used to assess NO adjunctive treatment (34, 35). Established biofilms were treated with 1 274 
mM SNP and 300/60 μg/ml AMC for 2 h and the viability of the remaining pneumococcal 275 
biofilm bacteria assessed by CFU enumeration. Treatment of ST124, 19F and D39 biofilms 276 
with the NO donor alone resulted in a 2-log reduction in viable bacteria, whereas treatment 277 
of 23F biofilms resulted in a 3-log reduction (Fig. 6). AMC treatment alone resulted in a 3-278 
log reduction in ST124 and 23F biofilm viability, and a 2-log reduction in 19F and D39 279 
biofilm viability (Fig. 6).  Combined NO/AMC treatment, however, resulted in a 3-log 280 
reduction in 19F and D39, a 5-log reduction in ST124, and complete killing of 23F when 281 
compared with untreated biofilms (Fig. 6), and a significant reduction in viable 282 
pneumococci in biofilms compared with antibiotic treatment alone (p < 0.05). 283 
 284 
Combined antibiotic and NO treatment enhanced ex vivo killing of S. pneumoniae on 285 
adenoid tissue. Adenoids have been shown to act as a reservoir for S. pneumoniae and 286 
biofilm bacteria, and may provide a source for infection in some cases of chronic otitis 287 
media (10, 11, 36).  Following research ethics committee approval and informed parental 288 
consent (NHS REC 09/H0501/74) we subsequently examined adenoid tissue ex vivo that 289 
was culture positive for S. pneumoniae from children <12 years of age undergoing 290 
adenoidectomy for the treatment of suspected inflammatory or infective ENT disease to 291 
evaluate the effect of NO on S. pneumoniae colonized mucosal epithelia (Fig. 7).  Adenoid 292 
sections (n=11) were treated with 100 μM of SNP alone, 300/60 μg/ml AMC alone, or 293 
treated with both NO and AMC to determine if NO adjunctive therapy increased antibiotic 294 
efficacy (Fig. 7). Treatment with 100 μM of the NO-donor SNP alone did not significantly 295 
reduce colonized pneumococci determined by CFUs (p=0.722) and AMC treatment alone 296 
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resulted in a 2-log reduction compared with the untreated adenoid (p=0.005).  However, 297 
similar to results with in vitro biofilms, combined NO and AMC resulted in a significant 298 
reduction of pneumococci CFUs on ex vivo adenoid tissue by nearly 3 logs (p=0.005) 299 
compared with untreated adenoid tissue and further reduced the number of CFUs 300 
compared with AMC alone (p=0.04).   301 
 302 
Treatment of in vitro S. pneumoniae biofilms with NO induced a change in 303 
translational and metabolic protein expression. Since low dose NO treatment of 48 h 304 
pneumococcal biofilms did not appear to be cytotoxic or induce dispersal we used a high-305 
throughput gel-free proteomic approach to investigate whether NO treatment induced 306 
changes in protein expression to shed further light on the potential mechanisms involved. 307 
Previous data from our lab demonstrated that a total of 112 proteins were differentially 308 
expressed during biofilm development using iTRAQ (inclusion criteria ≥3 peptide matches; 309 
>5% sequence coverage and a 50+ protein score; p<0.05) (33). Of these, 13 proteins were 310 
differentially expressed in established pneumococcal biofilms treated with NO for 2 h, 311 
compared with biofilms treated with HBSS alone (Fig. 8). Eighty five percent (11/13) of 312 
these proteins were involved in S. pneumoniae translation or metabolism (Figure 9a). Five 313 
ribosomal proteins, all of which demonstrated significantly decreased expression in the 314 
biofilm phenotype, exhibited increased expression following NO treatment, suggesting a 315 
modulation of translational capacity similar to planktonic levels (33). Additionally, 6 316 
metabolism-associated proteins were differentially expressed following NO treatment: 3-317 
ketoacyl-(acyl-carrier-protein) reductase and PTS system fructose-specific II ABC 318 
components were upregulated upon NO treatment, whereas arginine deiminase (ArcA), a 319 
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PTS system mannose specific IID component, and 2 individual alcohol dehydrogenases 320 
exhibited decreased expression following NO treatment. The significant reduction in ArcA 321 
expression is of particular interest given its >4-fold increase in expression during biofilm 322 
growth (33). Two other proteins, a SPFH domain-containing protein and a hypothetical 323 
protein were also identified as having increased expression following NO treatment. These 324 
data were further supported by the qualitative identification of 12 proteins with 325 
differential expression following NO treatment including 7 associated with pneumococcal 326 
metabolism (Figure 9b).  327 
 328 
Discussion 329 
Consistent with other studies, S. pneumoniae biofilms were more tolerant to 330 
antibiotic treatment than planktonic pneumococci, including an antibiotic commonly used 331 
to treat otitis media (13, 20, 37).  However, pneumococcal biofilm antibiotic tolerance was 332 
significantly diminished (by up to 2 logs) when accompanied by adjunctive treatment with 333 
a low concentration of NO. Additionally, we demonstrated biochemically that reduced 334 
viability of pneumococci in planktonic and biofilm growth conditions was mediated by NO, 335 
and the oxidative breakdown products of NO, nitrite and nitrate, did not mimic this effect.  336 
Although NO treatment reduced in vitro pneumococcal biofilm CFUs, our data suggest that 337 
the anti-pneumococcal effect was not due to a dispersal of bacteria.  Rather, higher 338 
concentrations of NO demonstrated a direct antibacterial effect on pneumococcal growth. 339 
Treatment with 1 mM SNP resulted in a decrease in biofilm viability by up to 3 logs, and in 340 
the number of viable cells in the surrounding supernatant. These data were commensurate 341 
with CLSM and SEM imaging which demonstrated no obvious changes in biofilm 342 
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ultrastructure, but did reveal a significant reduction in biofilm viability. A similar response 343 
was observed using the structurally distinct NO donor, DEA/NO.  The reduced antibacterial 344 
response in the presence of the NO scavenger cPTIO, and the lack of response to nitrite and 345 
nitrate, indicated that the antimicrobial effects were indeed NO-mediated, and not 346 
associated with the formation of NO3- and NO2- which have also been shown to increase 347 
antibiotic efficacy in P. aeruginosa biofilms (38). The specificity of the NO-mediated 348 
response, along with the reduction in the planktonic growth rate observed with ≥500 μM of 349 
SNP, suggest a direct effect on growth and/or regulation of metabolism.   350 
We also investigated the hypothesis that low concentrations of NO could enhance 351 
antibiotic efficacy in the treatment of pneumococcal biofilms.  In vitro S. pneumoniae 352 
biofilms were more tolerant than planktonic pneumococci to AMC, an antibiotic commonly 353 
used to treat pneumococcal infections, commensurate with other studies (20, 21). Results 354 
indicated that the addition of 1 mM SNP significantly enhanced antibiotic efficacy by  1 to 2 355 
logs in each of four strains tested, three of which represent serotypes (14, 19F and 23F) 356 
that are predominantly isolated from paediatric ENT patients and are associated with 357 
developing antibacterial recalcitrance (34, 35). Thus, when combined with NO, antibiotic 358 
tolerance within the biofilm was significantly diminished.  359 
Pneumococcal interactions with epithelial cells have been shown to be important for 360 
colonization and biofilm formation (12, 13), and pneumococci are commonly present on 361 
adenoids from children with chronic OM or OSA (10, 11). We therefore used adenoid upper 362 
respiratory mucosal epithelial tissue colonized with pneumococci to further determine if a 363 
combination of NO and AMC might enhance pneumococcal killing using a lower 364 
concentration than for in vitro biofilms.  Treatment of ex vivo adenoid tissue culture 365 
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positive for pneumococcus and rinsed to remove unattached bacteria, resulted in a 366 
significant reduction in pneumococcal CFUs on adenoid sections treated with antibiotic 367 
alone, but not NO-donor alone on treated tissue from the same adenoid sample.  When 368 
combined however, NO/AMC treatment resulted in a significantly enhanced reduction in 369 
CFUs. These results suggest that low-concentrations of NO rendered biofilm pneumococci 370 
more susceptible to antibiotic killing. These results are also consistent with other data 371 
showing that NO reduced S. pneumoniae viability in vivo using iNOS knock-out mice (32). 372 
The difference in susceptibility to S. pneumoniae bacteremia and lung infection between 373 
wild-type and iNOS-/- mice following intravenous infection versus intranasal infection may 374 
be due to the differential effects of inducible and constitutive NO production by endothelial 375 
and epithelial cells, suggesting that NO concentrations in the host are tissue dependent and 376 
regulated locally, and that NO in different mucosal sites is important in anti-pneumococcal 377 
host responses. 378 
NO is constitutively synthesised in the respiratory epithelium and upregulated in 379 
response to infection or inflammation (39).  Since S. pneumoniae is highly adapted to the 380 
upper airway, a compartment characterised by higher constitutive NO concentrations 381 
compared with the lower airways as evidenced by exhaled breath analysis (40), it is likely 382 
that this bacterium has the ability to respond to NO.  Moreover, since epithelial cells also 383 
produce iNOS, we speculate that exogenous NO may combine with endogenous NO levels to 384 
achieve the higher concentrations of NO sufficient to produce an enhanced anti-385 
pneumococcal response observed in vitro.  386 
NO signaling has been shown to elicit different responses in bacterial biofilms, 387 
however its role in mediating dispersal from a biofilm by the reversal of a genetically 388 
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determined program inducing biofilm development via cyclic di-GMP (c-di-GMP) has 389 
garnered significant interest due to its potential as a treatment strategy for biofilm-390 
associated infections (24).  In the model biofilm bacterium P. aeruginosa the NO dispersal 391 
response results in increased motility and metabolic activity characteristic of the 392 
planktonic (colonizing) phenotype allowing propagation to new sites within an 393 
environmental niche (41).  The single cell phenotype, as well as the increased metabolic 394 
and replicative capacity associated with the dispersed planktonic bacteria, are 395 
hypothesized to reduce biofilm antibiotic tolerance following NO treatment. Treatment of 396 
pneumococcal biofilms with low concentrations of the NO donor, SNP (100 nM to 100 μM), 397 
shown to disperse biofilms of other bacterial species resulted in no significant changes in 398 
biomass or viability at these concentrations.  This is unsurprising since S. pneumoniae is a 399 
non-motile bacterium, which lacks proteins possessing the common EAL, GGDEF and HD-400 
GYP domains that are involved in the turnover of the secondary messenger c-di-GMP 401 
known to mediate dispersal in other bacteria (27, 28).   402 
Rather, proteomic analyses suggested that NO induced a shift to a planktonic-like 403 
profile in a subset of proteins, notably those involved in metabolism and translation.  404 
Proteomic analyses of S. pneumoniae remaining within biofilms following treatment with a 405 
low concentration (100 μM) of NO indicated that 13 of 112 quantitatively identified 406 
proteins were differentially expressed, indicating that NO was not directly cytotoxic at 407 
concentrations of 100 μM.  The increased expression of five ribosomal proteins indicated 408 
up-regulation of translational capacity, which was previously shown to be substantially 409 
down-regulated in established pneumococcal biofilms (33). We previously hypothesized 410 
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that the decreased translation exhibited by the biofilm phenotype may contribute to 411 
antibiotic tolerance in the biofilm mode of growth in S. pneumoniae (33, 41, 42).  412 
Six additional proteins differentially expressed after NO treatment play a role in 413 
pneumococcal metabolism. Arginine deiminase (ArcA) and two alcohol dehydrogenases 414 
(Adh) were notably decreased. In our previous study, expression of these proteins was 415 
markedly increased during biofilm formation, and may compensate for the dramatic 416 
reduction in glycolytic activity observed in S. pneumoniae biofilms by up-regulating 417 
arginine and pyruvate metabolism (33).  Similar to the differential expression of 418 
translational proteins, the increased expression of metabolic proteins following NO 419 
treatment suggested that pneumococcus differentially modulates metabolism in planktonic 420 
and biofilm modes of growth.  Qualitatively, seven other metabolic proteins exhibited 421 
differential expression following NO treatment, compared with untreated biofilms.  422 
However these proteins were below the threshold of >3 peptides required for inclusion in 423 
the quantitative iTRAQ dataset. Nonetheless, taken together these data suggest that while 424 
high concentrations of NO elicit a direct antibacterial effect, low dose NO may be involved 425 
in regulation of metabolism via a currently unknown signaling pathway.   426 
The decreased expression of arginine deiminase following NO treatment is of 427 
particular interest. Regulation of S. pneumoniae arginine metabolism appears to be distinct 428 
from other bacteria and involves the regulators ArgR1, ArgR2 and AhrC (43, 44). ArgR1 is a 429 
transcriptional regulator of the arginine deminase system (ADS) consisting of arginine 430 
deiminase (arcA), ornithine carbamoyltransferase (arcB) and carbamate kinase (arcC) that 431 
mediate arginine acquisition and virulence in pneumococcus. Abrupt changes in arginine 432 
concentrations were recently shown to induce differential transcription of >450 genes in 433 
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Streptococcus gordonii, many of which were involved in adhesion and biofilm development 434 
(45). Furthermore, the difference in the effect of NO on two of the strains of pneumococcus 435 
used in our experiments is consistent with D39 and Serotype 14 having variable 436 
disruptions in arginine regulators ArgR1 and ArgR2 (43, 44).    437 
We speculate that NO may play a novel role in arginine metabolism and biofilm 438 
development in S. pneumoniae, and in regulating growth in pneumococcus. Our results 439 
suggest that low concentrations of NO modulate pneumococcal growth, possibly making 440 
dormant bacteria within the biofilm metabolically active and more susceptible to antibiotic 441 
killing. However, an alternative explanation is that the production of OONO- may contribute 442 
to the antibacterial effects of NO on pneumococcus since the antibacterial effect was 443 
reduced in the presence of the peroxynitrite (OONO-) scavenger L-methionine.  Elevated 444 
OONO- levels have also been found to be associated with the dispersal response and cell 445 
death in P. aeruginosa (27).  Peroxynitrite is a potent pro-oxidant and cytotoxic species 446 
produced by the interaction of superoxide (O2-) and NO.  Compromised pneumococcal 447 
superoxide dismutase (SOD) activity may lead to enhanced formation of O2- and 448 
subsequent reaction with host NO leading to the production of OONO-, a reaction that 449 
normally takes place in human macrophages (46). Peroxynitrite was a putative mediator of 450 
NO induced cytotoxic damage in pneumococcal infected microglial cell cultures in vitro and 451 
in vivo using pneumococcal mutants for pyruvate oxidase (spxB), and the arginine 452 
metabolism mutant carB in mice (22).  Intriguingly, these authors made the novel 453 
observation that pneumococcus can release NO, suggesting that NO is an endogenous 454 
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pneumococcal metabolite. Our previous proteomic analyses indicated pyruvate oxidase, 455 
which produces H2O2, was also markedly upregulated in pneumococcal biofilms (33).  456 
A MerR-like transcriptional factor NmlRsp required for NO defense was identified in 457 
S. pnuemoniae D39 using the NO donor S-nitrosoglutathione (GSNO) (47).  There was no 458 
evidence of a MER-like transcriptional protein in our proteomic data, however the role of 459 
NmlRsp was subsequently noted to have broader functional roles including a role in H2O2 460 
production and in arginine biosynthesis (48). 461 
The NO donor SNP has been widely utilized for a number of clinical applications, 462 
primarily through its use as a vasodilator, however, prolonged treatment and/or high 463 
doses have been suggested to pose a risk of cyanide-mediated cytotoxicity (49, 50). The 464 
decomposition of SNP to cyanide has also been shown to be slow (<2.5% over 72 h) when 465 
protected from direct exposure to high intensity/natural light (51). For the purpose of our 466 
initial study SNP was used as a suitable NO-donor to explore the actions of NO on 467 
pneumococcal biofilms since relatively low doses were applied for a short period (26, 27). 468 
Furthermore, treatment with equimolar concentrations of KCN had no effect on 469 
pneumococcal growth indicating that any observed responses to SNP were not the result of 470 
cyanide toxicity (52). However, future studies investigating NO-mediated anti-471 
pneumococcal effects with alternative donors, such as Cephalosporin-3´-diazeniumdiolate 472 
NO-Donor Prodrugs, which have been specifically designed to release NO at sites of 473 
bacterial infection may offer better choices for clinical use (53). 474 
The results of our study are consistent with other studies showing high 475 
concentrations of NO were toxic to bacteria including pneumococcus (32).  However, to our 476 
knowledge our study is the first to show that: 1) planktonic and biofilm S. pneumoniae 477 
 22
responded differentially to low and high concentrations of NO; 2) the anti-pneumococcal 478 
response was not induced by nitrite or nitrate, but was NO specific; 3) unlike other 479 
bacteria, low concentrations of NO did not elicit a dispersal response by biofilm S. 480 
pneumoniae; 4) a low concentration of NO altered the protein expression profile of biofilm 481 
pneumococci; and 5) when accompanied by adjunctive treatment with NO, pneumococcal 482 
sensitivity to antibiotic treatment was enhanced in vitro and ex vivo.  These results suggest 483 
that at lower concentrations, NO perturbs pneumococcal biofilm metabolism, but at higher 484 
concentrations NO is toxic to S. pneumoniae.  Targeted adjunctive NO treatment may be a 485 
candidate novel therapy for reducing biofilm tolerance by pneumococcus.   486 
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Figure 1: SNP treatment of in vitro pneumococcal biofilms reduced biofilm viability 662 
and biomass. 48h S. pneumoniae serotype 14 in vitro biofilms were treated with SNP for 2 663 
hours, and the biomass assessed by absorbance (OD600) and viability measured by CFU/ 664 
cm2. A significant reduction in total biomass and the number of viable cells remaining 665 
within the biofilm was observed following 1 mM SNP treatment. ***p≤0.001. 666 
 667 
Figure 2: SNP treatment of in vitro S. pneumoniae biofilms reduced the viable cell 668 
population in the surrounding supernatant.  The viability of 48h S. pneumoniae serotype 669 
14 in vitro biofilm and supernatant populations was measured by CFU enumeration 670 
following treatment with 1 mM SNP. SNP treatment significantly reduced both the biofilm 671 
and supernatant populations. *p≤0.05. 672 
 673 
Figure 3: In vitro S. pneumoniae biofilms treated with SNP demonstrated reduced 674 
viability and no evidence of dispersal. 48h S. pneumoniae serotype 14 in vitro biofilms 675 
were treated with 1 mM SNP for 2 hours then imaged using confocal microscopy and 676 
Live/Dead staining. 1 mM SNP-treated biofilms (b) demonstrated no obvious change in 677 
biomass when compared with untreated biofilms (a), however, a reduction in the number 678 
of Syto9-stained live bacteria in the 1 mM SNP-treated biofilms (d) was reduced in 679 
comparison with untreated biofilms (c), commensurate with CFU enumeration data. 680 
Scanning electron microscopy with Alcian Blue staining further demonstrated no obvious 681 
changes in biofilm ultrastructure between untreated (e) and 1 mM SNP-treated (f) biofilms 682 
(4,000x magnification; scale bar: 10 μm). 683 
 684 
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Figure 4: SNP treatment reduced the in vitro S. pneumoniae planktonic growth rate. S. 685 
pneumoniae serotype 14 in vitro planktonic cultures were treated with SNP during 686 
exponential growth phase, and the growth rate was measured by the change in absorbance 687 
(OD595) over 2 hours, and compared with the untreated growth rate. A significant 688 
reduction in growth rate was observed using 500 μM SNP, and complete cessation of 689 
growth was observed with concentrations greater than 5 mM. *p≤0.05; ****p≤0.0001. 690 
 691 
Figure 5: The response of S. pneumoniae to treatment with SNP was NO-mediated. a) 692 
S. pneumoniae serotype 14 exponential planktonic cultures were treated with the nitric 693 
oxide (NO) donors SNP, DEA/NO, nitrate and nitrite, and the CN- anion control potassium 694 
cyanide (KCN) over 2 hours. Significant decreases in the growth rate were observed upon 695 
treatment with two independent NO donors, SNP and DEA/NO, indicating that the response 696 
was NO-mediated. KCN treatment had no effect on growth rate confirming the response to 697 
SNP was not CN- mediated (p=0.528). Sodium nitrate (p=0.321) and sodium nitrite 698 
(p=0.078) treatments also had no effect on growth rate suggesting that nitrate and nitrite, 699 
respectively, were not utilised as sources of NO.  Finally, the addition of b) the NO-700 
scavenger carboxy-PTIO, and c) the peroxynitrite scavenger L-methionine reduced the 701 
response to SNP treatment suggesting the response may be mediated by either NO or 702 
peroxynitrite.  *≤0.05; **≤0.01; ***≤0.001. 703 
 704 
Figure 6: Adjunctive treatment of S. pneumoniae in vitro biofilms with SNP enhanced 705 
antibiotic efficacy. 48h S. pneumoniae serotype 14 (ST124), 19F, 23F and D39 in vitro 706 
biofilms were treated for 2 hours and the remaining viable cells measured by CFU 707 
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enumeration. When used separately both SNP and AMC treatment reduced the viable 708 
biofilm cell population, however, combined SNP and AMC treatment resulted in a further 709 
significant reduction in viability. *p≤0.05.  710 
 711 
Figure 7: Adjunctive treatment of S. pneumoniae biofilms on ex vivo adenoid tissue 712 
with SNP enhanced antibiotic efficacy. Adenoid tissue samples (n=11) were dissected 713 
into four equal sections (each with a similar proportion of luminal surface) treated for 2 714 
hours, and the viability of S. pneumoniae was measured by CFU enumeration. SNP 715 
treatment alone had no significant effect on viable pneumococci (p=0.722), whereas AMC 716 
treatment alone resulted in a significant reduction (p=0.005).  Combined SNP and AMC 717 
treatment however, resulted in enhanced antibiotic efficacy (p=0.041). *p≤0.05 (Wilcoxon 718 
Signed Ranks test). 719 
 720 
Figure 8: Treatment of S. pneumoniae in vitro biofilms with SNP resulted in the 721 
differential expression of a small subset of quantitatively identified proteins. 722 
Comparative iTRAQ analyses of SNP treated (100 M SNP/2 hours) and untreated S. 723 
pneumoniae serotype 14 7-day old in vitro biofilms quantitatively identified 112 proteins of 724 
which 13 were differentially expressed following treatment. 725 
 726 
Figure 9: Treatment of S. pneumoniae in vitro biofilms with SNP resulted in a change 727 
in metabolic and translation protein expression levels. Comparative iTRAQ analyses of 728 
SNP treated (100 μM SNP/2 hours) and untreated S. pneumoniae serotype 14 in vitro 729 
biofilms a) quantitatively identified 13 differentially expressed proteins, and b) 730 
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qualitatively identified 12 differentially expressed proteins following treatment. 731 
Quantitative inclusion criteria: ≥3 peptide matches, ≥50 protein score, ≥5% sequence 732 
coverage (p<0.05). Qualitative inclusion criteria: 2 peptide matches, ≥50 protein score, 733 
≥5% sequence coverage (p<0.05). Comparative protein data with >1.3 and <0.77 ratios 734 
identified as having differential protein expression. 735 









